v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Cash flows from operating activities      
Net Income (Loss) $ (13,678,735) $ (4,649,635)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 12,654 6,568 $ 26,272
Stock-based compensation expense 2,042,196 53,434  
Write-off of in-process research and development 7,357,294 0  
Change in fair value contingent consideration (1,164,864) 0  
Changes in operating assets and liabilities:      
Operating lease right-of-use assets 32,718 28,767  
Prepaid expenses and other assets (211,924) (14,719)  
Prepaid research and development 28,833 12,395  
Accounts payable 680,824 479,267  
Operating lease liabilities (35,745) (30,729)  
Accrued expenses and other current liabilities 833,219 247,634  
Net cash used in operating activities (4,103,530) (3,867,018)  
Cash flows from investing activities      
Purchases of equipment and improvements (13,399) 0  
Purchases of investments - marketable securities 0 (8,432,571)  
Maturities of investments - marketable securities 21,506,365 5,120,757  
Acquired in-process research and development (438,624) 0  
Net cash provided by (used in) investing activities 21,054,342 (3,311,814)  
Cash flows from financing activities      
Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs 0 397,607  
Deferred offering costs 0 (30,608)  
Net cash provided by financing activities 0 366,999  
Net increase (decrease) in cash and cash equivalents 16,950,812 (6,811,833)  
Cash and cash equivalents at beginning of period 56,490,579 9,165,179 9,165,179
Cash and cash equivalents at end of period 73,441,391 2,353,346 $ 56,490,579
Supplemental disclosures of cash flow information      
Issuance costs 0 407,329  
CorHepta transaction costs 175,000 0  
Contingent consideration 3,270,579 0  
Deferred offering costs $ 0 $ 167,721